Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
I Couldn't Get PrEP, and Now I'm Living With HIV

I'll never forget the day I discovered that I had HIV. It was a Monday, last October. I'd recently moved to San Francisco but was in Los Angeles for work when I got the call. The voice of the case manager on the other end sounded shaky, like he felt sorry for having to tell me something so important over the phone. My head swirled. How could this happen?

Published
28 November 2017
From
The Body
Medicines Excitement in the Netherlands – New Health Minister announces firm action on “absurd” medicines pricing

The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing.

Published
27 November 2017
From
Medicines Law & Policy
UNAIDS announces nearly 21 million people living with HIV now on treatment

In the year 2000, just 685 000 people living with HIV had access to antiretroviral therapy. By June 2017, around 20.9 million people had access to the life-saving medicines. Such a dramatic scale-up could not have happened without the courage and determination of people living with HIV demanding and claiming their rights, backed up by steady, strong leadership and financial commitment.

Published
20 November 2017
From
UNAIDS press release
HIV in West and Central Africa – the state of an epidemic left behind

The UNAIDS, Médecins Sans Frontières (MSF) and African Union 18-month catch-up plan aims to increase treatment access and reduce mortality in West and Central Africa.

Published
10 November 2017
From
Avert
Why do some HIV drugs cost so much in the US? Pharma, insurers, advocacy groups and consumers weigh in

As open enrollment begins November 1, millions of Americans are comparing insurance plans available on the Affordable Care Act insurance marketplace. Prescription copayments and which medications a health plan covers are key considerations for people living with HIV and for those taking regular prescription medications. The cost to the consumer is very different, however, from the price that insurers negotiate with pharmaceutical companies, and the debate around drug pricing has hit national headlines in recent years with cases like EpiPen and Daraprim. Drug pricing is a complicated issue, with pharmaceutical companies on one side, patient activists on the other, and consumers oftentimes stuck somewhere in the middle.

Published
03 November 2017
From
BETA blog
Uganda: ARVs Stock-Out Sparks Fear of Mass Drug Resistance

Civil society organisations and people living with HIV/Aids have warned that almost a million Ugandans could develop resistance to first-line anti-retroviral therapy if nothing is done about the nation-wide stock-out of drugs.

Published
01 November 2017
From
AllAfrica
MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug

Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, sofosbuvir and daclatasvir, for as low as US$1.40 per day, or US$120 per 12-week treatment course.

Published
31 October 2017
From
Intellectual Property Watch
Close to 3 million people access hepatitis C cure

On the eve of the World Hepatitis Summit in Brazil, WHO reports increasing global momentum in the response to viral hepatitis. A record 3 million people were able to obtain treatment for hepatitis C over the past two years, and 2.8 million more people embarked on lifelong treatment for hepatitis B in 2016.

Published
31 October 2017
From
World Health Organization
Gilead Continues To Block Ireland From Sourcing Generic Truvada

Gilead Sciences, the company that supplies Ireland with the drug Truvada, will have a full court hearing in mid-October to determine whether the Irish Health and Safety Executive (HSE) can source a generic analogue of the drug from the pharmaceutical giant’s competitors. In July, GCN reported that Gilead was taking legal action to stop the HSE from securing generic drug from Actavis and Mylan, the company’s competitors, for the purposes of HIV prevention as PrEP.

Published
16 October 2017
From
Gay Community News
STI warning as clinics close in London and self-testing is delayed

People are being denied care at overburdened sexual health clinics after a wave of closures and huge delays to a controversial new self-testing scheme for diseases such as herpes and syphilis, health experts are warning.

Published
16 October 2017
From
The Guardian
← First12345...115Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.